Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab in patients with PD-1/PD-L1 refractory advanced melanoma.

The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California.

The open-label, single-arm ATLAS-IT-05 study enrolled heavily pretreated patients with unresectable stage IIIB to IV melanoma, all of whom had received prior immunotherapy. Treatment demonstrated clinically meaningful anti-tumour activity alongside a manageable safety profile.

Key outcomes included an objective response rate of 13.6% and a clinical benefit rate of 40.9% among evaluable patients. Median progression-free survival was 6.3 months, with several durable responses ongoing beyond 24 months and six patients achieving disease stabilisation.

The safety profile was consistent with known effects of intratumoral immunotherapy and pembrolizumab, with common adverse events including injection-site reactions, fatigue, pruritus, hypotension, and anemia. No treatment-related adverse events resulted in discontinuation of pembrolizumab.